Clinical Lymphoma, Myeloma & Leukemia最新文献

{"title":"A Review of Clonal Relationships in Myeloproliferative Neoplasms With Co-Mutations of JAK2, CALR or MPL and BCR::ABL1","authors":"Mohammadamin Noorafrooz ,&nbsp;Sanaz Ghods ,&nbsp;Robert Peter Gale ,&nbsp;Ramin Noorafrooz","doi":"10.1016/j.clml.2024.11.007","DOIUrl":"10.1016/j.clml.2024.11.007","url":null,"abstract":"<div><div><em>BCR::ABL1-</em>negative myelo-proliferative neoplasms (MPNs) are characterized by mutations in <em>JAK2, CALR</em>, or <em>MPL</em>. Usually these mutations are co-exclusive of each other and of <em>BCR::ABL1</em>. We reviewed clonal interactions in 177 subjects with mutations in <em>JAK2, CALR</em>, or <em>MPL</em> and <em>BCR::ABL1</em> including <em>JAK2/BCR::ABL1</em> (<em>N</em> = 142), <em>CALR/BCR::ABL1</em> (<em>N</em> = 31), <em>MPL/BCR::ABL1</em> (<em>N</em> = 3). Co-mutations can arise in the same clone or in different sub-clones. In this review we used clonality data, mutation sequencing and therapy response evaluation to address this question. We found that in subjects with <em>JAK2/BCR::ABL1</em> co-mutations there is a complex, branched clonal evolution. In contrast, in subjects with <em>CALR/BCR::ABL1,</em> co-mutations are in different sub-clones. There are too few data in subjects with <em>MPL/BCR::ABL1</em> to critically analyze. However, indirect methods for assessing clonality limit our conclusions. Understanding clonal architecture of MPNs with co-mutations is needed to understand the underlying biology and give appropriate therapy.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 4","pages":"Pages 249-253"},"PeriodicalIF":2.7,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142913881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics, Risk Factors and Outcomes of Invasive Fungal Disease in Critically III Patients with Hematological Malignancy: A Retrospective Study","authors":"Changzhen Yang ,&nbsp;Jie Xiong ,&nbsp;Jiakai Wang ,&nbsp;Hongying Bi ,&nbsp;Jianyu Fu ,&nbsp;Xian Liu ,&nbsp;Chun Long ,&nbsp;Qianfu Zhang ,&nbsp;Dehua He ,&nbsp;Yan Tang ,&nbsp;Xu Liu","doi":"10.1016/j.clml.2024.12.005","DOIUrl":"10.1016/j.clml.2024.12.005","url":null,"abstract":"<div><h3>Background</h3><div>Invasive fungal disease (IFD) poses significant challenges for critically ill patients with hematological malignancies (HMs). However, there is limited research on the clinical characteristics, risk factors, and outcomes of IFD within this population.</div></div><div><h3>Method</h3><div>A retrospective study was conducted at a tertiary center in China. The study focused on patients with HMs admitted to the intensive care unit (ICU) between 2014 and 2022.</div></div><div><h3>Results</h3><div>A total of 239 patients were enrolled, among whom 105 (43.9%) were diagnosed with IFD. Further classification revealed that 64.8%, 31.4%, and 3.8% were classified as possible, probable, and proven IFD, respectively. Patients with IFD had significantly prolonged ICU stays compared to those without IFD (median: 4.9 vs. 2.9 days, <em>P</em> &lt; .001). Notably, there was no statistically significant difference in 28-day mortality between the patients with and without IFD (44.8% vs. 54.5%, <em>P</em> = .907). Hypertension, mechanical ventilation (MV) duration exceeding 48 hours, and an extended interval between deterioration and ICU admission emerged as independent risk factors for IFD.</div></div><div><h3>Conclusion</h3><div>IFD is a common complication in critically ill patients with HM and is associated with prolonged length of ICU stay. Additionally, hypertension, prolonged MV duration and delayed ICU transfer are independent risk factors of IFD in these patients.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 4","pages":"Pages e214-e221"},"PeriodicalIF":2.7,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions | Venetoclax + Obinutuzumab Therapy in Chronic Lymphocytic Leukemia.","authors":"Andrew H Lipsky, Nicole Lamanna","doi":"10.1016/j.clml.2024.11.016","DOIUrl":"https://doi.org/10.1016/j.clml.2024.11.016","url":null,"abstract":"<p><p>In the past decade, the treatment paradigm for chronic lymphocytic leukemia (CLL) has markedly shifted from traditional chemoimmunotherapy towards targeted therapies.¹ A fixed-duration, targeted regimen with venetoclax, a potent oral BCL-2 inhibitor, combined with obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody (Ven-Obi), has become the standard to beat for time-limited therapy in CLL. Ven-Obi allows for the rapid induction of remissions with high rates of undetectable minimal residual disease (uMRD) in patients across different treatment settings. This strategy enables the discontinuation of therapy while maintaining treatment-free remissions for several years in many patients. With up to 6-year data now available from the pivotal phase 3 trial of this combination in CLL, this review aims to examine the evolving role of this strategy in CLL management, including updated data for safety and efficacy in randomized trials in both the frontline and relapsed/refractory (R/R) settings. We also explore real-world data for this combination, and review related issues, such as MRD monitoring, the potential for venetoclax retreatment or consolidative strategies and evaluate ongoing trials comparing this regimen as a standard of care control arm versus novel (including all-oral) therapeutic combinations.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas.","authors":"Nicole Foley, Peter A Riedell, Nancy L Bartlett, Amanda F Cashen, Brad S Kahl, Todd A Fehniger, Anne Fischer, Chaz Moreno, Jingxia Liu, Kenneth R Carson, Neha Mehta-Shah","doi":"10.1016/j.clml.2024.11.015","DOIUrl":"https://doi.org/10.1016/j.clml.2024.11.015","url":null,"abstract":"<p><strong>Introduction: </strong>Histone deacetylase inhibitors (HDACi) and combination chemotherapy are independently used to treat relapsed/refractory (R/R) lymphoma. In vitro studies suggest that the addition of HDACi to platinum-based chemotherapy is synergistic.</p><p><strong>Patients and methods: </strong>We conducted a phase I study of romidepsin, gemcitabine, oxaliplatin and dexamethasone (Romi-GemOxD) in R/R aggressive lymphomas with an expansion cohort in T-cell lymphomas. A total of 24 patients were enrolled with median age 70; 6 patients had diffuse large B-cell lymphoma (DLBCL) and 18 patients had peripheral T-cell lymphomas (PTCL-NOS: 10; angioimmunoblastic T-cell lymphoma [AITL]: 7; ALK-negative anaplastic large cell lymphoma: 1). Patients had received a median of 2 prior lines of therapy and 10 patients were refractory to last line of therapy.</p><p><strong>Results: </strong>Using a standard 3 + 3 dose escalation design, the maximum tolerated dose of romidepsin was determined to be 10 mg/m² in combination with GemOxD. There were no unexpected toxicities. The most common grade ≥ 3 treatment-emergent adverse events were thrombocytopenia (79%) and lymphopenia (46%). The overall response rate for Romi-GemOxD was 52% (12/23) with complete response (CR) rate of 43% (10/23). All 6 patients with AITL evaluable for efficacy achieved CR. Durable responses were seen in patients with AITL, PTCL-NOS and DLBCL. Without additional therapy, 4 patients remained in remission for more than 2 years, with 3 patients progressing at 46.5, 30.8, and 32.6 months and 1 remission ongoing at 83 months. A total of 4 patients proceeded to consolidative stem cell transplant following induction.</p><p><strong>Conclusion: </strong>Romi-GemOxD represents a well-tolerated, time-limited, effective option for patients, particularly for those with AITL in which durable responses were seen. NCT02181218.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence Assessment of Chest Radiographs for COVID-19.","authors":"Koji Sasaki, Guillermo Garcia-Manero, Masayuki Nigo, Elias Jabbour, Farhad Ravandi, William G Wierda, Nitin Jain, Koichi Takahashi, Guillermo Montalban-Bravo, Naval G Daver, Philip A Thompson, Naveen Pemmaraju, Dimitrios P Kontoyiannis, Junya Sato, Sam Karimaghaei, Kelly A Soltysiak, Issam I Raad, Hagop M Kantarjian, Brett W Carter","doi":"10.1016/j.clml.2024.11.013","DOIUrl":"10.1016/j.clml.2024.11.013","url":null,"abstract":"<p><strong>Background: </strong>The sensitivity of reverse-transcription polymerase chain reaction (RT-PCR) is limited for diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Chest computed tomography (CT) is reported to have high sensitivity; however, given the limited availability of chest CT during a pandemic, the assessment of more readily available imaging, such as chest radiographs, augmented by artificial intelligence may substitute for the detection of the features of coronavirus disease 2019 (COVID-19) pneumonia.</p><p><strong>Methods: </strong>We trained a deep convolutional neural network to detect SARS-CoV-2 pneumonia using publicly available chest radiography imaging data including 8,851 normal, 6,045 pneumonia, and 200 COVID-19 pneumonia radiographs. The entire cohort was divided into training (n = 13,586) and test groups (n = 1510). We assessed the accuracy of prediction with independent external data.</p><p><strong>Results: </strong>The sensitivity and positive predictive values of the assessment by artificial intelligence were 96.8% and 90.9%, respectively. In the first external validation of 204 chest radiographs among 107 patients with confirmed COVID-19, the artificial intelligence algorithm correctly identified 174 (85%) chest radiographs as COVID-19 pneumonia among 97 (91%) patients. In the second external validation with 50 immunocompromised patients with leukemia, the higher probability of the artificial intelligence assessment for COVID-19 was correlated with suggestive features of COVID-19, while the normal chest radiographs were closely correlated with the likelihood of normal chest radiographs by the artificial intelligence prediction.</p><p><strong>Conclusions: </strong>The assessment method by artificial intelligence identified suspicious lung lesions on chest radiographs. This novel approach can identify patients for confirmatory chest CT before the progression of COVID-19 pneumonia.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and Leukemia Volume 24, Issue 8, August 2024, Pages 523-530]","authors":"Kathryn Lurain ,&nbsp;Talal El Zarif ,&nbsp;Ramya Ramaswami ,&nbsp;Amin H. Nassar ,&nbsp;Elio Adib ,&nbsp;Noha Abdel-Wahab ,&nbsp;Nikita Chintapally ,&nbsp;Claire E. Drolen ,&nbsp;Tatyana Feldman ,&nbsp;Tarek Haykal ,&nbsp;Caroline A. Nebhan ,&nbsp;Swetha Kambhampati ,&nbsp;Mingjia Li ,&nbsp;Arjun Mittra ,&nbsp;Michael Lorentsen ,&nbsp;Chul Kim ,&nbsp;Alexandra Drakaki ,&nbsp;Michael Morse ,&nbsp;Douglas B. Johnson ,&nbsp;Ankit Mangla ,&nbsp;Alex F. Herrera","doi":"10.1016/j.clml.2024.10.011","DOIUrl":"10.1016/j.clml.2024.10.011","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"24 12","pages":"Page 873"},"PeriodicalIF":2.7,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142703186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Socioeconomic Status and Healthcare Resource Availability on Survival in Older (≥66 years) Non-Hispanic Black Patients Versus Non-Hispanic White Patients With Multiple Myeloma","authors":"Sophia S. Li ,&nbsp;Robert Schuldt ,&nbsp;Faiza Zafar ,&nbsp;Tu My To ,&nbsp;Archibong Yellow-Duke ,&nbsp;Alina Levine ,&nbsp;Allicia Girvan ,&nbsp;Shelli Spence ,&nbsp;Joseph Mikhael","doi":"10.1016/j.clml.2024.11.011","DOIUrl":"10.1016/j.clml.2024.11.011","url":null,"abstract":"<div><h3>Background</h3><div>Several factors contribute to the known disparities in overall survival (OS) between non-Hispanic Black (NHB) patients and non-Hispanic White (NHW) patients with multiple myeloma (MM).</div></div><div><h3>Patients and Methods</h3><div>To explore whether socioeconomic status (SES) and healthcare resource (HCR) availability impacts OS, this retrospective study used linked Surveillance, Epidemiology, and End Results (SEER)-Medicare claims and Area Health Resource Files to identify NHB and NHW patients aged ≥66 years with MM (newly diagnosed 6/1/2013-12/31/2017). Continuous Medicare A and B enrollment until 12/31/2019 or preceding death was required.</div></div><div><h3>Results</h3><div>In total, 6,609 patients were identified; 15.6% were NHB. At baseline, NHB patients were younger, more likely to be female, had higher Charlson Comorbidity Index (CCI), and were more likely to live in census tracts with lower education attainment and higher poverty percentages than NHW patients.</div><div>Unadjusted median OS by race/ethnicity for NHB patients versus NHW patients was 2.76 versus 3.01 years (hazard ratio [HR]: 1.08; <em>P</em> = .063). In the adjusted model, older age at diagnosis (<em>P</em> &lt; .001), male sex (<em>P</em> = .02), and higher CCI (<em>P</em> &lt; .001) increased risk of death. Poverty (<em>P</em> = .02) and number of active medical doctors per 100,000 (<em>P</em> = .003) were significant but not clinically meaningful. OS HR by race reversed directionality when adjusted for demographics, SES and HCR availability (HR: 0.92; <em>P</em> = .12).</div></div><div><h3>Conclusion</h3><div>Several factors, including SES and HCR availability, significantly influenced OS and may drive disparities in care for patients with MM. Further research on larger datasets is needed.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 4","pages":"Pages 285-292.e1"},"PeriodicalIF":2.7,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy","authors":"Gohar S. Manzar ,&nbsp;Stephanie O. Dudzinski ,&nbsp;Alison K. Yoder ,&nbsp;Aaron Seo ,&nbsp;Lewis F. Nasr ,&nbsp;Hind Rafei ,&nbsp;Melody R. Becnel ,&nbsp;Krina K. Patel ,&nbsp;Hans C. Lee ,&nbsp;Gregory P. Kaufman ,&nbsp;Mahmoud M. Gaballa ,&nbsp;Jing Christine Ye ,&nbsp;Neeraj Saini ,&nbsp;Sheeba K. Thomas ,&nbsp;Behrang Amini ,&nbsp;Robert Z. Orlowski ,&nbsp;Bouthaina S. Dabaja ,&nbsp;Chelsea C. Pinnix ,&nbsp;Jillian R. Gunther ,&nbsp;Susan Y. Wu ,&nbsp;Penny Q. Fang","doi":"10.1016/j.clml.2024.11.010","DOIUrl":"10.1016/j.clml.2024.11.010","url":null,"abstract":"<div><h3>Background</h3><div>The prognosis of multiple myeloma involving the central nervous system (CNS-MM) is poor. We report outcomes of CNS-MM treated with CNS-directed radiation therapy (RT).</div></div><div><h3>Methods</h3><div>We retrospectively reviewed patients with CNS-MM treated with CNS-directed RT from 2015 to 2024. CNS-MM was defined as having radiographic leptomeningeal or parenchymal disease, and/or pathologic CSF involvement. Complete response (CR) constituted having no atypical cells in CSF or resolution of radiographic disease. Otherwise, patients were categorized with partial response (PR) based on imaging, or stable disease (SD). The Kaplan-Meier method was used to estimate survival.</div></div><div><h3>Results</h3><div>Of 45 patients with CNS-MM, 28 (62.2%) had high-risk disease. Median overall survival (OS) was 3.7 months (range: 0.4-52.2) postdiagnosis of CNS-MM. Most patients (<em>n</em> = 22, 48.9%) underwent craniospinal irradiation; 9 received whole brain RT (20%), and the others received focal brain or spine RT. The median dose was 20 Gy (2-30 Gy) in 10 fractions (1-15). Due to death or discharge to hospice before further follow-up of treatment efficacy (<em>n</em> = 24), only 21 patients (46.7%) were evaluable post-RT with adequate CSF or radiographic follow-up. For these evaluable patients, post-RT CR occurred in 14 patients (66.7%), PR in 5 (23.8%), and SD in 2 (9.5%). For patients with CR after RT, the median OS was 7.3 months (3-52.2) from CNS-MM diagnosis. Focal brain CNS-MM associated with improved OS and likelihood of attaining long-term survival with CNS CR.</div></div><div><h3>Conclusion</h3><div>Aggressive multimodality therapy including RT may induce durable CNS control in a small subset of patients with CNS-MM, a high-risk population.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 4","pages":"Pages 271-284"},"PeriodicalIF":2.7,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives.","authors":"Johannes M Waldschmidt, Leo Rasche, K Martin Kortüm, Hermann Einsele","doi":"10.1016/j.clml.2024.11.012","DOIUrl":"https://doi.org/10.1016/j.clml.2024.11.012","url":null,"abstract":"<p><p>Despite significant advancements, multiple myeloma (MM) remains incurable, and there is still a pressing need for new therapeutic strategies with highly selective mechanisms of action and balanced off-target toxicity. In recent years, the development of \"off-the-shelf\" bispecific antibodies (bsAbs) has significantly enhanced our ability to treat relapsed or refractory MM. Teclistamab, elranatamab (both BCMA × CD3), and talquetamab (GPRC5D × CD3) are approved for treating MM patients who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Meanwhile, the range of available bsAbs is rapidly expanding, offering patients and healthcare providers a broad selection of options that vary in target antigens, binding domains, construct designs, dosing regimens, and side effects. As linvoseltamab, alnuctamab, and ABBV-383 (all BCMA × CD3), as well as forimtamig (GPRC5D × CD3) and cevostamab (FcRH5 × CD3) progress through late-stage clinical development, emerging trispecific antibodies are now available that target either 2 different MM-associated antigens or provide additional co-stimulatory signals to prevent T-cell exhaustion. Despite this plethora of therapeutic options, resistance to bsAbs is an inevitability, and the optimal positioning of these drugs within the current MM treatment landscape remains to be determined. In this review, we examine the available data on all clinically accessible bsAbs, evaluating their potential, current limitations, and implications for efficacy and safety, with the aim of achieving deeper responses and longer overall survival for MM patients.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Let's Agree to Disagree: Reflections From the Smoldering Multiple Myeloma Session at the International Myeloma Society Study Summit","authors":"Hira Mian ,&nbsp;Marc S. Raab","doi":"10.1016/j.clml.2024.11.009","DOIUrl":"10.1016/j.clml.2024.11.009","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 4","pages":"Pages 240-242"},"PeriodicalIF":2.7,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}